Finally, the TFAP2E gene was the least altered in the NSCLC patients (0.9%); the observed changes included mostly mutations and amplification in LUAD (1%), as well as mutations and deletions in LUSC (0.6%) cases (Figure 9G). This evidence concerns the gene TFAP2E and non-small cell lung carcinoma.